SEMA4D compromises blood–brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Multiple sclerosis (MS) is a chronic neuroinflammatory disease characterized by immune cell infiltration of CNS, blood-brain barrier (BBB) breakdown, localized myelin destruction, and progressive neuronal degeneration. There exists a significant need to identify novel therapeutic targets and strategies that effectively and safely disrupt and even reverse disease pathophysiology. Signaling cascades initiated by semaphorin 4D (SEMA4D) induce glial activation, neuronal process collapse, inhibit migration and differentiation of oligodendrocyte precursor cells (OPCs), and disrupt endothelial tight junctions forming the BBB. To target SEMA4D, we generated a monoclonal antibody that recognizes mouse, rat, monkey and human SEMA4D with high affinity and blocks interaction between SEMA4D and its cognate receptors. In vitro, anti-SEMA4D reverses the inhibitory effects of recombinant SEMA4D on OPC survival and differentiation. In vivo, anti-SEMA4D significantly attenuates experimental autoimmune encephalomyelitis in multiple rodent models by preserving BBB integrity and axonal myelination and can be shown to promote migration of OPC to the site of lesions and improve myelin status following chemically-induced demyelination. Our study underscores SEMA4D as a key factor in CNS disease and supports the further development of antibody-based inhibition of SEMA4D as a novel therapeutic strategy for MS and other neurologic diseases with evidence of demyelination and/or compromise to the neurovascular unit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Brinkmann, V., Billich, A., Baumruker, T., Heining, P., Schmouder, R., Francis, G., Aradhye, S., & Burtin, P. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3248 · Cited by 1,273
Jäger, A., Dardalhon, V., Sobel, R. A., Bettelli, E., & Kuchroo, V. K. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901906 · Cited by 783 · cited 1×
“To enrich for Th1 cell differentiation (Axtell et al., 2010; Jager et al., 2009), cells were stimulated with 20 μg/ml PLP139–151, 20 μg/ml anti-”
Semaphorins and their receptors in immune cell interactions
Suzuki, K., Kumanogoh, A., & Kikutani, H. (2008) · Nature Immunology · doi:10.1038/ni1553 · Cited by 400 · cited 2×
“SEMA4D is a 150-kDa transmembrane protein expressed on the surface of T and B cells, monocytes, platelets, and professional antigen-presenting cells, such as dendritic cells (Kikutani and Kumanogoh, 2003; Suzuki et al., 2008).”
Liang, X., Draghi, N. A., & Resh, M. D. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.5319-03.2004 · Cited by 255
Vos, C. M. P., Geurts, J. J. G., Montagne, L., van Haastert, E. S., Bö, L., van der Valk, P., Barkhof, F., & de Vries, H. E. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.06.012 · Cited by 188 · cited 1×
“BBB compromise in MS patients is detectable not only in focal lesions, but also in diffuse white matter abnormalities identified by postmortemMRI, suggesting that dysfunction in BBBmay be a significant contributor to disease pathology (Vos et al., 2005).”
Leech, S., Kirk, J., Plumb, J., & McQuaid, S. (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2006.00781.x · Cited by 137 · cited 1×
“forms of the disease (Soon et al., 2007; Leech et al., 2007).”
Okuno, T., Nakatsuji, Y., Moriya, M., Takamatsu, H., Nojima, S., Takegahara, N., Toyofuku, T., Nakagawa, Y., Kang, S., Friedel, R. H., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903302 · Cited by 119
Cited by
Synaptic degeneration in Alzheimer disease
Tzioras, M., McGeachan, R. I., Durrant, C. S., & Spires-Jones, T. L. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-022-00749-z · Cited by 504
Semaphorins in Adult Nervous System Plasticity and Disease
Carulli, D., de Winter, F., & Verhaagen, J. (2021) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2021.672891 · Cited by 137
Feigin, A., Evans, E. E., Fisher, T. L., Leonard, J. E., Smith, E. S., Reader, A., Mishra, V., Manber, R., Walters, K. A., Kowarski, L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01919-8 · Cited by 67
Self-citationSemaphorin 4D is upregulated in neurons of diseased brains and triggers astrocyte reactivity
Evans, E. E., Mishra, V., Mallow, C., Gersz, E. M., Balch, L., Howell, A., Reilly, C., Smith, E. S., Fisher, T. L., & Zauderer, M. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02509-8 · Cited by 44
Self-citationWhite Matter in Crisis: Oligodendrocytes and the Pathophysiology of Multiple Sclerosis
García-Domínguez, M. (2025) · Cells · doi:10.3390/cells14181408 · Cited by 13
Metadata
- Authors
- Smith, E. S., Jonason, A., Reilly, C., Veeraraghavan, J., Fisher, T., Doherty, M., Klimatcheva, E., Mallow, C., Cornelius, C., Leonard, J. E., Marchi, N., Janigro, D., Argaw, A. T., Pham, T., Seils, J., Bussler, H., Torno, S., Kirk, R., Howell, A., Evans, E. E., Paris, M., Bowers, W. J., John, G., & Zauderer, M.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 73
- Pages
- 254-268
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2002875429
- Cited by
- 121
- References
- 8
- FWCI
- 6.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SEMA4D compromises blood–brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease. https://app.cochat.ai/papers/10.1016/j.nbd.2014.10.008
- The paper
- Smith, E. S., Jonason, A., Reilly, C., Veeraraghavan, J., Fisher, T., Doherty, M., Klimatcheva, E., Mallow, C., Cornelius, C., Leonard, J. E., Marchi, N., Janigro, D., Argaw, A. T., Pham, T., Seils, J., Bussler, H., Torno, S., Kirk, R., Howell, A., . . . Zauderer, M. (2015). SEMA4D compromises blood–brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease. Neurobiology of Disease. https://doi.org/10.1016/j.nbd.2014.10.008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.